Recent Advances In Parkinson’s Disease

Healthcare Recent Advances In Parkinson’s Disease William A. Haseltine Contributor Opinions expressed by Forbes Contributors are their own. New! Follow this author to stay notified about their latest stories.

Got it! Aug 17, 2022, 03:08pm EDT | New! Click on the conversation bubble to join the conversation Got it! Share to Facebook Share to Twitter Share to Linkedin Brain neurotransmitters. Parkinson. org Parkinson’s disease is a progressive neurodegenerative disease that induces symptoms of shaking, stiffness, uncontrollable movement, poor coordination, and balance.

Development of Parkinson’s disease occurs at the age of 60 onward. This brain disorder develops as early as 50 years old in 5-10% of cases. Parkinson’s affects nerve cells deep in the brain called basal ganglia.

These cells are responsible for producing dopamine and transmitting messages for bodily functions. Current treatments replace dopamine to the brain of a patient. Such treatments have been successful at reducing symptoms of nausea.

At present, there is no cure for this brain disorder. It is important to manage Parkinson’s early on, one new discovery that may help is the use of diagnostic tools. Early detection of Parkinson’s Disease Biomarkers can be used as a diagnostic tool for identifying the stage of a disease in a patient with abnormal conditions.

Researchers at Kobe and Hiroshima University developed a biomarker that detects early Parkinson’s in patients’ blood serum samples such it is a quick and inexpensive process as outlined in figure 1. Figure 1. Changes in P450 expression https://neurosciencenews.

com/parkinsons-biomarker-20673/ The test relies on cytochrome P450-metabolites to measure fluorescent patterns. Cytochrome P450 is an enzyme with the vital role of the detoxification of xenobiotics, cellular metabolism and homeostasis (Manikandan et al. , 2018).

Researchers discovered that expression of P450 changes in the body depending on the disease. It is speculated that this change affects both the quantity and quality of metabolites in a patient’s body, essential for carrying out different biological activities. This study shows that there is in fact a distinction in specific metabolite patterns found for healthy vs.

Parkinson’s disease patients (fig. 1). MORE FOR YOU CDC: Salmonella Outbreak Has Left 279 Ill, 26 Hospitalized In 29 States Canadians End Up In ICU After Attending ‘Covid Party’ White House Mandates Pfizer Vaccines for Millions of Citizens .

. . Before the FDA Clinical or Safety Reviews Have Been Made Public Inhibition Assay Figure 2.

P450 inhibition assay process https://neurosciencenews. com/parkinsons-biomarker-20673/ To detect the changes in quality and quantity of P450-related metabolites, researchers successfully carried out an inhibition assay. For the assay, 12 different human P450s were mixed with a serum sample and fluorescent substrate to induce a reaction.

They found a difference in the fluorescence patterns for both groups (i. e. healthy people and Parkinson’s patients).

Specifically, there was an inhibition of fluorescence with the Parkinson’s disease patient samples. These patients have P450-related metabolites that do not react with the fluorescent substrate, hence the inhibition (fig. 2).

This new liquid biopsy technique distinguishes people without Parkinson’s to people who have this disorder. Model Analysis Figure 3. Results of analysis using Parkinson’s disease model rats and humans with Parkinson’s .

. . [+] disease.

https://neurosciencenews. com/parkinsons-biomarker-20673/ The same tests were run on rat models with the disease as well as patients suffering from other neurodegenerative and inflammatory diseases. Researchers found an 85-88% accuracy in detecting Parkinson’s for both human and animal subjects.

Conclusion Parkinson’s disease continues to affect the lives of millions worldwide. With incidences of Parkinson’s increasing with age, it is crucial to administer quick and effective solutions in the early stages of this brain disorder to inhibit it from worsening. There is currently no cure for Parkinson’s disease therefore, early detection is vital for inhibiting progression.

Follow me on Twitter or LinkedIn . William A. Haseltine Editorial Standards Print Reprints & Permissions.